CVS (CVS HEALTH CORPORATION)
Insider Trading Activity
Every open-market purchase and sale reported by CVS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-29 | James David Clark | SVP, Cont & Chief Acct Officer | F | — | — |
| 2026-06-01 | Amy Compton-Phillips | EVP, Chief Medical Officer | F | — | — |
| 2026-06-01 | Brian Newman | EVP, Chief Financial Officer | F | — | — |
| 2026-05-22 | FERNANDO AGUIRRE | Director | D | — | — |
| 2026-05-21 | LARRY ROBBINS | Director | Sell | — | — |
| 2026-05-15 | LARRY ROBBINS | Director | A | — | — |
| 2026-05-15 | Douglas H. Shulman | Director | A | — | — |
| 2026-05-15 | C DAVID BROWN II | Director | A | — | — |
| 2026-05-15 | Anne A. Finucane | Director | A | — | — |
| 2026-05-15 | ALECIA A DECOUDREAUX | Director | A | — | — |
| 2026-05-15 | GUY P SANSONE | Director | A | — | — |
| 2026-05-15 | Leslie V Norwalk | Director | A | — | — |
| 2026-05-15 | J SCOTT KIRBY | Director | A | — | — |
| 2026-05-15 | Jeffrey R. Balser | Director | A | — | — |
| 2026-05-15 | FERNANDO AGUIRRE | Director | A | — | — |
| 2026-05-15 | Michael F Mahoney | Director | A | — | — |
| 2026-05-15 | John E Gallina | Director | A | — | — |
| 2026-05-11 | Tilak Mandadi | EVP, Chief Exp & Tech Officer | Sell | — | — |
| 2026-04-02 | HEIDI B CAPOZZI | EVP and Chief People Officer | MIXED | — | — |
| 2026-04-02 | James David Clark | SVP, Cont & Chief Acct Officer | MIXED | — | — |
| 2026-04-02 | Amy Compton-Phillips | EVP, Chief Medical Officer | A | — | — |
| 2026-04-02 | J. David Joyner | President, CEO and Chair | MIXED | — | — |
| 2026-04-02 | Samrat S. Khichi | EVP, CPO and General Counsel | MIXED | — | — |
| 2026-04-02 | Tilak Mandadi | EVP, Chief Exp & Tech Officer | MIXED | — | — |
| 2026-04-02 | Steven H Nelson | EVP and President, Aetna | MIXED | — | — |
| 2026-04-02 | Brian Newman | EVP, Chief Financial Officer | A | — | — |
| 2026-04-02 | Prem S Shah | EVP and Group President | MIXED | — | — |
| 2026-03-20 | John E Gallina | Director | A | — | — |
| 2026-03-02 | J. David Joyner | President and CEO | F | — | — |
| 2026-03-02 | Samrat S. Khichi | EVP, CPO and General Counsel | F | — | — |
| 2026-01-27 | Steven H Nelson | EVP and President, Aetna | Buy | — | — |
| 2026-01-05 | Prem S Shah | EVP and Group President | F | — | — |
| 2025-12-02 | HEIDI B CAPOZZI | EVP and Chief People Officer | F | — | — |
| 2025-12-02 | ROGER N FARAH | Director | F | — | — |
| 2025-12-02 | Tilak Mandadi | EVP, Chief Exp & Tech Officer | F | — | — |
| 2025-12-02 | James David Clark | SVP, Cont & Chief Acct Officer | F | — | — |
| 2025-11-21 | FERNANDO AGUIRRE | Director | A | — | — |
| 2025-11-21 | Jeffrey R. Balser | Director | A | — | — |
| 2025-11-21 | C DAVID BROWN II | Director | A | — | — |
| 2025-11-21 | ALECIA A DECOUDREAUX | Director | A | — | — |
| 2025-11-21 | Anne A. Finucane | Director | A | — | — |
| 2025-11-21 | J SCOTT KIRBY | Director | A | — | — |
| 2025-11-21 | Michael F Mahoney | Director | A | — | — |
| 2025-11-21 | Leslie V Norwalk | Director | A | — | — |
| 2025-11-21 | LARRY ROBBINS | Director | A | — | — |
| 2025-11-21 | GUY P SANSONE | Director | A | — | — |
| 2025-11-21 | Douglas H. Shulman | Director | A | — | — |
| 2025-10-14 | HEIDI B CAPOZZI | EVP and Chief People Officer | Buy | — | — |
| 2025-09-02 | Tilak Mandadi | EVP, Chief Exp & Tech Officer | F | — | — |
| 2025-09-02 | Prem S Shah | EVP and Group President | F | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 5,195,261 | — |
| — | Non-Executive Chairman | 1,662,444 | — |
| — | President and CEO | 639,860 | — |
| — | EVP & General Counsel | 474,393 | — |
| — | EVP | 385,118 | — |
| — | Director | 326,462 | — |
| — | Executive Vice President | 293,003 | — |
| — | EVP and Chief Medical Officer | 234,855 | — |
| — | Director | 181,461 | — |
| — | President, CEO and Chair | 160,860 | — |
| — | Director | 147,575 | — |
| — | Chairman | 135,572 | — |
| — | Director | 129,316 | — |
| — | Director | 125,112 | — |
| — | EVP and Co-President of Retail | 124,383 | — |
| — | Director | 113,845 | — |
| — | Director | 112,217 | — |
| — | EVP&President-PharmacyServices | 109,675 | — |
| — | Chief Financial Officer | 101,411 | — |
| — | Director | 96,293 | — |
| — | EVP and President - Omnicare | 92,360 | — |
| — | EVP and Chief People Officer | 84,490 | — |
| — | President and CEO | 74,687 | — |
| — | Director | 73,318 | — |
| — | EVP & President-CVS/pharmacy | 72,843 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CVS quote page; the site-wide leaderboard is on the insider transactions hub.